Compare Mesoblast Limited (MESO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nuscale Power Corporation — how do they compare? Mesoblast Limited trades at $14.31 (market cap $1.75B), while Nuscale Power Corporation trades at $7.09 (market cap $3.00B). The key difference: Nuscale Power Corporation is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Nuscale Power Corporation for 29 Days on average.
| MESO | SMR | |
|---|---|---|
Market Cap | $1.75B | $3.00B |
Volume | 239,027 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $20.96 | $53.43 |
52-Week Low | $13.19 | $7.32 |
Typical Hold Time | 14 Days | 29 Days |
Enterprise Value | $1.83B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SMR stock trades at $7.23, down 5.74% on the day, reflecting a bearish technical trend and weak financial performance. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with a negative net income margin of -3,888.7%. Despite analyst consensus pointing to a $11.25 price target, recent news highlights an ongoing SEC investigation and intense competition in the small modular reactor market.
The outlook remains highly speculative, with significant execution risk and cash burn offsetting long-term potential in the nuclear energy sector. While institutional interest and a 50% buy rating suggest some optimism, the stock's high volatility and lack of profitability present substantial risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
